Comparative Pharmacology
Head-to-head clinical analysis: ANTEPAR versus PIPERAZINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTEPAR versus PIPERAZINE CITRATE.
ANTEPAR vs PIPERAZINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic